---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002403"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:43:25.859603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B

## Summary
- EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).
- REGEN-COV FY2021 U.S. net product sales ~$5.82B; Q4 sales ~$2.29B.
- Provided corporate update at J.P. Morgan conference; highlighted pipeline progress including Aflibercept 8mg Ph3 data expected 2H22.
- Dupixent annualizing at ~$6.6B run rate; three potential new Ph3 indications in 2022 (CSU, PN, EoE).
- Announced $3B share repurchase program in Nov 2021; over $7.5B repurchased since Nov 2019.

## SEC filing metadata
- accession: 0001104659-22-002403
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/0001104659-22-002403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/tm222431d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002403
- JSON: https://secwatch.observer/filing/0001104659-22-002403.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.